Two teams have independently provided preclinical proof of concept for using lysine-specific histone demethylase 1 inhibitors to treat acute myelogenous leukemia. One of the teams is now running a clinical trial of a generic monoamine oxidase inhibitor that counts the demethylase among its many targets, whereas at least four biotechs are advancing other more potent and selective inhibitors through preclinical development.